With skin in the game, Satsuma's partner offers buyout to get migraine spray to market

Even as Satsuma Pharmaceuticals searched for a savior after a series of late-stage trial failures put its future in doubt, the U.S. biotech never lost faith in the potential of its migraine spray. Now, the Japanese company behind the tech used to deliver the spray has stepped in to keep the dream alive.